Pharsight

Inlyta patents expiration

INLYTA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6534524 PF PRISM CV Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
Apr, 2025

(1 year, 6 months from now)

US8791140 PF PRISM CV Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyondazole suitable for the treatment of abnormal cell growth in mammals
Dec, 2030

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10570202 PF PRISM CV Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer
Feb, 2035

(11 years from now)

US10869924 PF PRISM CV PD-L1 antagonist combination treatments
Jan, 2037

(13 years from now)

Inlyta is owned by Pf Prism Cv.

Inlyta contains Axitinib.

Inlyta has a total of 4 drug patents out of which 0 drug patents have expired.

Inlyta was authorised for market use on 27 January, 2012.

Inlyta is available in tablet;oral dosage forms.

Inlyta can be used as axitinib in combination with avelumab for the first-line treatment of patients with advanced renal cell carcinoma, in combination with pembrolizumab for the first-line treatment of patients with advanced renal cell carcinoma.

The generics of Inlyta are possible to be released after 12 January, 2037.

Drugs and Companies using AXITINIB ingredient

Market Authorisation Date: 27 January, 2012

Treatment: In combination with pembrolizumab for the first-line treatment of patients with advanced renal cell carcinoma; Axitinib in combination with avelumab for the first-line treatment of patients with advan...

Dosage: TABLET;ORAL

How can I launch a generic of INLYTA before it's drug patent expiration?
More Information on Dosage

INLYTA family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic